Malcisbo is specialized on glycoengineering technologies to develop novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Our platform technology provides a tool to develop a strong pipeline of novel, cost-efficient vaccine products.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2010
  • Number of employees in Switzerland
    1-9
Key business